Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021
November 09 2021 - 9:00AM
Celsion Corporation (NASDAQ:
CLSN), a clinical-stage development company focused on
DNA-based immunotherapy and next-generation vaccines, announced
today that the Company will host a conference call at 11:00
a.m. ET on Monday, November 15, 2021 to discuss
financial results for third quarter ended September 30,
2021 and provide an update on product development programs
with GEN-1, a DNA-based immunotherapy, currently in Phase II
development for the localized treatment of advanced ovarian cancer
and PLACCINE, a proprietary synthetic, non-viral vaccine delivery
technology currently in preclinical studies. Celsion has
two platform technologies for the development of novel nucleic
acid-based immunotherapies and next generation infectious vaccines.
To participate in the call, interested parties
may dial 1-800-353-6461 (Toll-Free/North America) or
+1-334-323-0501 (International/Toll) and ask for the Celsion
Corporation Third Quarter 2021 Earnings Call (Conference Code:
4154518) to register ten minutes before the call is scheduled to
begin. The call will also be broadcast live on the internet
at www.celsion.com. The call will be archived for replay
on Monday, November 15, 2021 and will remain available
until November 29, 2021. The replay can be accessed at
+1-719-457-0820 or 1-888-203-1112 using Conference ID: 4154518 . An
audio replay of the call will also be available on the Company's
website, www.celsion.com, for 90 days after 2:00 p.m. ET
Monday, November 15, 2021.
About Celsion Corporation
Celsion is a fully integrated, clinical
stage biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies and
DNA-based therapies; and a platform for the development of nucleic
acid vaccines currently focused on SARS-CoV2. The company’s product
pipeline includes GEN-1, a DNA-based immunotherapy for the
localized treatment of ovarian cancer. ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, is under
investigator-sponsored development for several cancer
indications. Celsion also has two platform technologies
for the development of novel nucleic acid-based immunotherapies and
other anti-cancer DNA or RNA therapies. Both are novel synthetic,
non-viral vectors with demonstrated capability in nucleic acid
cellular transfection. For more information on Celsion,
visit www.celsion.com.
Forward-looking Statements
Forward-looking statements in this news release
are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including, unforeseen changes in the course
of research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data, particularly in small subgroups that are not statistically
significant; FDA and regulatory uncertainties and risks; the
significant expense, time and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in
the Celsion's periodic filings with the Securities
and Exchange Commission. Celsion assumes no obligation to
update or supplement forward-looking statements that become untrue
because of subsequent events, new information or otherwise.
Celsion Investor ContactJeffrey W.
Church609-482-2455jchurch@celsion.com
LHA Investor RelationsKim Sutton
Golodetz212-838-3777kgolodetz@lhai.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024